focus -WSS

focus

author：leisure time 2025-08-23 03:45:00 - browse：8

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： CVS is on a mission to consolidate health care. Will it work?

WSS

Inaction leaves children at risk from dangerous chemotherapy drug

A pediatrician calls for Congress to pass the child tax credit deal

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Readout Newsletter: Biotech news today

High breast density mammograms need follow

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

leisure time

focus

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Smaller biotechs seek to piggyback on weight loss drug boom

Medical records are filled with copy

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Hollywood unions extend contract negotiations for actors

STAT Summit: Meghan O’Rourke on making chronic illness visible

Psychedelics group wrestles with new pharma identity

Is there really a nursing shortage in the U.S.?

Affirmative action in medical school literally saved lives

Update the Apgar Score to remove skin color

hotspot

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Maisha Meds is a PBM, but don't call it that

FDA sets aggressive timeline for overhauling inspection procedures

Roivant's CEO is a star, but biotech's black hole persists

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Mass General, Mayo Clinic look to monetize custom

hotspot

entertainment

focus

hotspot